Free Trial

CRISPR Therapeutics (CRSP) News Today

$54.84
-0.40 (-0.72%)
(As of 05/28/2024 ET)
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0%
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 0%
Contrarius Investment Management Ltd Sells 37,808 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Contrarius Investment Management Ltd decreased its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 17.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 182,927 shares of the company's stock after selling 37,808 shares
7 Biotech Stocks to Put on Your Breakthrough Radar
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 0.9%
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 0.9%
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.2% on Analyst Downgrade
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 0.2% Following Analyst Downgrade
BNP Paribas Financial Markets Cuts Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
BNP Paribas Financial Markets lessened its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 67.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 42,290 shares of the company's stock after s
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 3.1% Following Analyst Downgrade
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 3.1% After Analyst Downgrade
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 6%
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 6%
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 1.5%
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 1.5%
Trexquant Investment LP Acquires New Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Trexquant Investment LP acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 132,385 shares of the
Charles Schwab Investment Management Inc. Acquires 15,085 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Charles Schwab Investment Management Inc. lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 2.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 653,023 shares of the company's stock after buying an additional 1
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.3%
CRSP May 2024 39.000 put
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Nikko Asset Management Americas Inc.
Nikko Asset Management Americas Inc. lowered its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,369,762 shares of the company's
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 0.3%
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.3%
Is CRISPR Therapeutics Stock a Buy?
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Hold" from Brokerages
CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has earned a consensus rating of "Hold" from the seventeen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, seven have given a hold
Farrow Financial Inc. Acquires Shares of 18,920 CRISPR Therapeutics AG (NASDAQ:CRSP)
Farrow Financial Inc. bought a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 18,920 shares of the company's stock, valued at approximately $1,184,000. Several other hedg
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.7%
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 2.7%
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 2.2%
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 2.2%
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 3.4%
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 3.4%
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 11.3%
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 11.3%
The 3 Best Cathie Wood Stocks to Buy in May 2024
Swiss National Bank Has $9.31 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)
Swiss National Bank decreased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 9.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 148,700 shares of the company's stock afte
Reynders McVeigh Capital Management LLC Has $5.76 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)
Reynders McVeigh Capital Management LLC raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 20.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,048 shares of the company's stock after purchas
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $95.00
Oppenheimer decreased their price target on shares of CRISPR Therapeutics from $102.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday.
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 2.1% After Analyst Downgrade
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.1% After Analyst Downgrade
FY2025 EPS Estimates for CRISPR Therapeutics AG Lowered by Analyst (NASDAQ:CRSP)
CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Investment analysts at Brookline Capital Management cut their FY2025 earnings estimates for CRISPR Therapeutics in a research report issued on Wednesday, May 8th. Brookline Capital Management analyst L. Cann now expects that the company will po
CRISPR Therapeutics (NASDAQ:CRSP) Receives Market Outperform Rating from JMP Securities
JMP Securities reaffirmed a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday.
CRISPR Therapeutics (NASDAQ:CRSP) Announces Earnings Results
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) announced its earnings results on Wednesday. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.08). The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $25.53 million. The business's revenue for the quarter was down 99.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.67) earnings per share.
CRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $65.00 at Wells Fargo & Company
Wells Fargo & Company cut their price target on shares of CRISPR Therapeutics from $70.00 to $65.00 and set an "equal weight" rating for the company in a report on Thursday.
Get CRISPR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

This Apple-like Innovator is Revolutionizing Healthcare (Ad)

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

CRSP Media Mentions By Week

CRSP Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRSP
News Sentiment

0.78

0.87

Average
Medical
News Sentiment

CRSP News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRSP Articles
This Week

22

9

CRSP Articles
Average Week

Get CRISPR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:CRSP) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners